Dr. Yingli Zhang 张英丽
Chief Physician, Associate Professor
Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of ovarian, cervical, endometrial, and vulvar cancers, including radical and super-radical procedures. Comprehensive care for advanced malignancies using chemotherapy, targeted therapy, and immunotherapy.
Dr. Zhang is Chief Physician, Associate Professor, and graduate supervisor at Zhejiang Cancer Hospital. Dr. Zhang serves as Party Branch Secretary and Deputy Director of the Gynecologic Oncology Department.
Professional roles
- Member, Chinese Medical Association
- Standing Committee Member, Uterine Body Tumor Professional Committee, China Anti-Cancer Association
- Chair, Youth Committee, Gynecologic Oncology Professional Committee, Zhejiang Anti-Cancer Association
Name order: in Chinese the family name comes first (Zhang Yingli). Papers usually list the name as Yingli Zhang or Zhang Y.
Selected publications
38 papers on PubMed matched by name and affiliation; 11 as first or senior author since 2016. Most recent first- or senior-author papers:
- Phytother Res, 2026 (senior author): Chaetocin Induces Ferroptosis in Cisplatin-Resistant Ovarian Cancer Cells Through Neddylation-Mediated TFRC Upregulation. PubMed 42734152
- Technol Cancer Res Treat, 2026 (senior author): Comparison of Different Maintenance Treatment Options for Newly Diagnosed BRCAwt Advanced Ovarian Cancer: A Retrospective Cohort Analysis. PubMed 41637212
- Comb Chem High Throughput Screen, 2026 (senior author): Uncovering ShuangZi Powder's Anti-Ovarian Cancer Mechanism: A Systems Biology and Experimental Approach. PubMed 41036756
- Pharmacol Res, 2025 (first author): The effects of synbiotics surpass prebiotics in improving inflammatory biomarkers in children and adults: A systematic review, meta-analysis, and meta-evidence of data from 5207 participants in 90 randomized controlled trials. PubMed 40581234
- Gynecol Oncol, 2025 (senior author): Therapeutically targeting endometrial cancer in preclinical models by ICAM1 antibody-drug conjugates. PubMed 40147093
- Discov Oncol, 2024 (senior author): The impact of different clinicopathologic factors and salvage therapies on cervical cancer patients with isolated para-aortic lymph node recurrence. PubMed 38427141
- Curr Cancer Drug Targets, 2024 (senior author): Real-world Study on the Effect of PARPi as Maintenance Therapy on Platinum Sensitivity after First- and Second-line Chemotherapy in Patients with Recurrent High-grade Serous Epithelial Ovarian Cancer. PubMed 38173064
- Transl Cancer Res, 2021 (senior author): Prognostic and clinical significance of Solute Carrier Family 7 Member 1 in ovarian cancer. PubMed 35116394
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion